PMID- 24417913
OWN - NLM
STAT- MEDLINE
DCOM- 20150106
LR  - 20151119
IS  - 2152-2669 (Electronic)
IS  - 2152-2669 (Linking)
VI  - 14
IP  - 3
DP  - 2014 Jun
TI  - High-dose vincristine sulfate liposome injection (Marqibo) Is not associated with 
      clinically meaningful hematologic toxicity.
PG  - 197-202
LID - S2152-2650(13)00474-6 [pii]
LID - 10.1016/j.clml.2013.10.012 [doi]
AB  - BACKGROUND: Vincristine sulfate liposome injection (VSLI) facilitates vincristine 
      dose intensification and densification, is active in untreated and relapsed 
      lymphoma, and has been approved in the United States for relapsed and refractory 
      acute lymphoblastic leukemia. Cancer- and concomitant chemotherapy-related 
      anemia, neutropenia, and thrombocytopenia in patients with hematologic malignancy 
      have complicated the evaluation of hematologic toxicity related to new drugs. 
      PATIENTS AND METHODS: We assessed the hematologic toxicity of VSLI 2.25 mg/m(2) 
      administered every 14 (cohort 1) or 7 (cohort 2) days in 54 patients with 
      metastatic uveal melanoma, a cancer not known to involve the bone marrow. 
      RESULTS: Cohort 2 received a greater median number of VSLI doses (6 vs. 4) within 
      a shorter median period (5.7 vs. 8.7 weeks), resulting in a larger median 
      cumulative exposure (22.6 vs. 17.7 mg) and near doubling of the median dose 
      density (2.2 vs. 4.0 mg/wk) compared with cohort 1. Despite greater VSLI exposure 
      and dose density, cohort 2 had a lower median decrease from baseline in the 
      neutrophil count and a greater increase from baseline in the platelet count 
      compared with cohort 1. Hematologic adverse events (AEs) were uncommon and mostly 
      grade 1 or 2 in severity. No grade 4 hematologic AEs developed. CONCLUSION: VSLI 
      at its approved dose resulted in a low incidence of clinically meaningful 
      hematologic toxicity. A near doubling of the median dose density did not have an 
      identifiable effect on the reported incidence and severity of hematologic AEs. 
      VSLI could be well suited for use combined with myelosuppresive drugs and for 
      patients unable to tolerate peripheral blood cytopenia.
CI  - Copyright (c) 2014 Elsevier Inc. All rights reserved.
FAU - Deitcher, Olivia R
AU  - Deitcher OR
AD  - Talon Therapeutics, Inc, South San Francisco, CA.
FAU - Glaspy, John
AU  - Glaspy J
AD  - University of California, Los Angeles, CA.
FAU - Gonzalez, Rene
AU  - Gonzalez R
AD  - University of Colorado Denver, Aurora, CO.
FAU - Sato, Takami
AU  - Sato T
AD  - Thomas Jefferson University, Philadelphia, PA.
FAU - Bedikian, Agop Y
AU  - Bedikian AY
AD  - University of Texas MD Anderson Cancer Center, Houston, TX.
FAU - Segarini, Karen
AU  - Segarini K
AD  - Talon Therapeutics, Inc, South San Francisco, CA.
FAU - Silverman, Jeffrey
AU  - Silverman J
AD  - Talon Therapeutics, Inc, South San Francisco, CA.
FAU - Deitcher, Steven R
AU  - Deitcher SR
AD  - Talon Therapeutics, Inc, South San Francisco, CA. Electronic address: 
      srdeitcher@hotmail.com.
LA  - eng
PT  - Journal Article
DEP - 20131115
PL  - United States
TA  - Clin Lymphoma Myeloma Leuk
JT  - Clinical lymphoma, myeloma & leukemia
JID - 101525386
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Liposomes)
RN  - 5J49Q6B70F (Vincristine)
RN  - Uveal melanoma
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents, Phytogenic/*administration & dosage/*adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - *Blood Cell Count
MH  - Erythrocyte Indices/*drug effects
MH  - Female
MH  - Humans
MH  - Liposomes
MH  - Male
MH  - Melanoma/*blood/*drug therapy/pathology
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Treatment Outcome
MH  - Uveal Neoplasms/*blood/*drug therapy/pathology
MH  - Vincristine/*administration & dosage/*adverse effects
OTO - NOTNLM
OT  - Anemia
OT  - Liposome
OT  - Neutropenia
OT  - Thrombocytopenia
OT  - Vincristine
EDAT- 2014/01/15 06:00
MHDA- 2015/01/07 06:00
CRDT- 2014/01/15 06:00
PHST- 2013/06/24 00:00 [received]
PHST- 2013/10/17 00:00 [revised]
PHST- 2013/10/21 00:00 [accepted]
PHST- 2014/01/15 06:00 [entrez]
PHST- 2014/01/15 06:00 [pubmed]
PHST- 2015/01/07 06:00 [medline]
AID - S2152-2650(13)00474-6 [pii]
AID - 10.1016/j.clml.2013.10.012 [doi]
PST - ppublish
SO  - Clin Lymphoma Myeloma Leuk. 2014 Jun;14(3):197-202. doi: 
      10.1016/j.clml.2013.10.012. Epub 2013 Nov 15.